B-Lymphocyte Depletion with Rituximab and Beta-Cell Function: Two-Year Results
- Mark D. Pescovitz, MD, PhD,
- Carla J. Greenbaum, MD,
- Brian Bundy, PhD,
- Dorothy J. Becker, MD,
- Stephen E. Gitelman, MD,
- Robin Goland, MD,
- Peter A. Gottlieb, MD,
- Jennifer B. Marks, MD,
- Antoinette Moran, MD,
- Philip Raskin, MD,
- Henry Rodriguez, MD,
- Desmond A. Schatz, MD,
- Diane K. Wherrett, MD,
- Darrell M. Wilson, MD,
- Jeffrey P. Krischer, PhD,
- Jay S. Skyler, MD⇑,
- and The Type 1 Diabetes TrialNet Anti-CD20 Study Group
- From: Indiana University School of Medicine, Indianapolis, Indiana (MDP, HR); Benaroya Research Institute, Seattle, Washington (CJG); University of South Florida, Tampa, Florida (BB, HR, JPK); University of Pittsburgh, Pittsburgh, Pennsylvania (DJB); University of California San Francisco, San Francisco, California (SEG); Columbia University, New York, New York (RG); University of Colorado Barbara Davis Center for Childhood Diabetes, Aurora Colorado (PAG); University of Miami Diabetes Research Institute, Miami, Florida (JBM, JSS); University of Minnesota, Minneapolis, Minnesota (AM); University of Texas Southwestern Medical School, Dallas, Texas (PR); University of Florida, Gainesville, Florida (DAS); Hospital for Sick Children, University of Toronto, Toronto, Ontario (DKW); and Stanford University, Stanford, California (DMW).
- Corresponding author: Jay S. Skyler, E-mail: ,
Objective We previously reported that selective depletion of B-lymphocytes with rituximab, an anti-CD20 monoclonal antibody, slowed decline of beta-cell function in recent-onset type 1 diabetes mellitus (T1DM) at one year. Subjects were followed further to determine whether there was persistence of effect.
Research Design and Methods Eighty-seven subjects (ages 8-40) were randomly assigned to, and 81 received, infusions of rituximab or placebo on days 1, 8, 15, and 22. The primary outcome – baseline-adjusted mean 2-hour area under the curve (AUC) serum C-peptide during a mixed meal tolerance test (MMTT) at one year – showed higher C-peptide AUC with rituximab versus placebo. Subjects were further followed with additional MMTTs every 6 months.
Results The rate of decline of C-peptide was parallel between groups, but shifted by 8.2 months in rituximab treated subjects. Over 30 months, AUC, insulin dose, and HbA1c were similar for rituximab and placebo. However, in evaluating change in C-peptide over the entire follow-up period, the rituximab group means were significantly larger as compared within assessment times to the placebo group means using a global test (p = 0.03). Odds ratio for loss of C-peptide to < 0.2 nmol/L following rituximab was 0.565 (p= 0.064). B-lymphocytes recovered to baseline values by 18 months. Serum IgG levels were maintained in the normal range but IgM levels were depressed.
Conclusions Like several other immunotherapeutic approaches tested, in recent-onset T1DM, rituximab delays the fall in C-peptide, but does not appear to fundamentally alter the underlying pathophysiology of the disease.
- Received March 13, 2013.
- Accepted September 6, 2013.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.